Published Year: 2020
Global Liquid Biopsy Market: Focus on Market Segmentation by Product Type, by Indication Type, by Te
The global liquid biopsy market is projected to reach $12,933 million by 2030 from $2588.6...
Market Research Report
A quick peek into the report
Table of Contents
1.1 Product Definition
1.1.1 Definitions
1.1.2 Inclusion and Exclusion
1.2 Market Overview
1.3 Historical Perspective
1.4 Significant Technologies
1.5 Classification of Molecular Diagnostics
1.6 Global Footprint
1.7 Global Molecular Diagnostics Market Size and Forecast - Realistic, Optimistic, and Conservative Growth Scenario
1.7.1 Realistic Growth Scenario
1.7.2 Conservative Growth Scenario
1.8 Future Potential
1.8.1 Optimistic Growth Scenario
1.9 Market Dynamics
1.9.1 Impact Analysis
1.9.2 Market Drivers
1.9.2.1 A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
1.9.2.2 Growth in the Biomarker Identification Market and Advancements in Molecular Techniques
1.9.2.3 Increase in Awareness and Acceptance of Personalized Medicines on a Global Level
1.9.2.4 Significant External Funding for Executing Research and Development Exercises
1.9.3 Market Restraints
1.9.3.1 Uncertain Reimbursement Scenario
1.9.3.2 Lack of High-Complexity Testing Centers
1.9.3.3 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
1.9.4 Market Opportunities
1.9.4.1 Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations
1.9.4.2 Rise of Next-Generation Ultrasensitive Molecular Diagnostics
1.9.4.3 Novel Revenue Streams
1.10 COVID-19 Impact on Global Molecular Diagnostics Market
1.10.1 Impact on Market Size
1.10.2 Impact on Molecular Diagnostic Practices
1.11 Competitive Landscape
1.11.1 Acquisitions
1.11.2 Synergistic Activities
1.11.3 Product Launches and Upgradations
1.11.4 Business Expansion
1.11.5 Market Share Analysis, by Company
1.11.6 Growth Share Analysis, by Technology
1.12 Industry Insights
1.12.1 Legal Requirements and Framework in the U.S.
1.12.2 FDA Regulations
1.12.3 Legal Requirements and Framework in Europe
1.12.3.1 U.K.
1.12.3.2 Germany
1.12.4 Legal Requirements and Framework in Asia-Pacific
1.12.4.1 China
1.12.4.2 Japan
1.12.4.2.1 Pharmaceuticals and Medical Devices Agency (PMDA)
1.12.4.2.2 Ministry of Health, Labour, and Welfare (MHLW)
1.12.4.3 India
1.13 Patent Analysis
1.13.1 Patent Filing Trend
2.1 Overview
2.1.1 Systems
2.1.2 Kits and Consumables
2.1.3 Software and Other Products
3.1 Overview
3.1.1 Laboratory Testing
3.1.2 Point-of-Care Testing
4.1 Overview
4.1.1 Polymerase Chain Reaction (PCR)
4.1.2 Next-Generation Sequencing
4.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
4.1.4 Microarray
4.1.5 In-Situ Hybridization (ISH)
4.1.6 Immunohistochemistry (IHC)
4.1.7 Other Technologies
5.1 Overview
5.1.1 Core Molecular Diagnostics
5.1.1.1 Infectious Disease
5.1.1.1.1 Respiratory Infections
5.1.1.1.1.1 Influenza A and B
5.1.1.1.1.2 COVID-19 Infections
5.1.1.1.1.3 Respiratory Syncytial Virus
5.1.1.1.1.4 Mycoplasma Infections
5.1.1.1.1.5 Pertussis
5.1.1.1.1.6 Other Respiratory Infections
5.1.1.1.2 Sexual Transmitted Infections(STI)
5.1.1.1.2.1 Common Pathogens Associated with Sexually Transmitted Infection
5.1.1.1.2.2 Hepatitis B
5.1.1.1.2.3 HIV-AIDS
5.1.1.1.2.4 HPV
5.1.1.1.2.5 Herpes Simplex Virus
5.1.1.1.2.6 Neisseria Gonorrhoeae
5.1.1.1.2.7 Other STIs
5.1.1.2 Hereditary Genetic Testing
5.1.1.3 Blood Donor Screening
5.1.1.4 Oncology
5.1.1.5 Human Leukocyte Antigen (HLA) Testing
5.1.1.6 Other Molecular Diagnostics Applications
5.1.2 Reproductive Genetics
5.1.2.1 Carrier Screening
5.1.2.2 Non-Invasive Pre-Natal Testing (NIPT)
5.1.2.3 Pre-Implantation Genetic Testing
5.1.2.4 Infertility Genetic Testing
5.1.3 Companion Diagnostics (CDx)
5.1.4 Liquid Biopsy
5.1.5 Other Applications
6.1 Overview
6.1.1 Hospitals
6.1.1.1 Hospitals, by Respiratory Infections Molecular Diagnostics Market
6.1.1.1.1 Hospitals, by Influenza A and B
6.1.1.1.2 Hospitals, by COVID-19 Infections
6.1.1.1.3 Hospitals, by Respiratory Syncytial Virus
6.1.1.1.4 Hospitals, by Mycoplasma Infection
6.1.1.1.5 Hospitals, by Pertussis
6.1.1.1.6 Hospitals, by Other Respiratory Infections
6.1.1.2 Hospitals Sexually Transmitted Infections (STIs) Market
6.1.1.2.1 Hospitals, by Hepatitis B
6.1.1.2.2 Hospitals, by HIV AIDS
6.1.1.2.3 Hospitals, by HPV
6.1.1.2.4 Hospitals, by Herpes Simplex Virus(HSV)
6.1.1.2.5 Hospitals, by Neisseria gonorrhoeae
6.1.1.2.6 Hospitals, by Other STIs
6.1.2 Diagnostic Centers
6.1.2.1 Diagnostic Centers, by Respiratory Infections Molecular Diagnostics Market
6.1.2.1.1 Diagnostic Centers, by Influenza A and B
6.1.2.1.2 Diagnostic Centers, by COVID-19 Infections
6.1.2.1.3 Diagnostic Centers, by Respiratory Syncytial Virus
6.1.2.1.4 Diagnostic Centers, by Mycoplasma Infection
6.1.2.1.5 Diagnostic Centers, by Pertussis
6.1.2.1.6 Diagnostic Centers, by Other Respiratory Infections
6.1.2.2 Diagnostic Centers Sexually Transmitted Infections (STIs) Market
6.1.2.2.1 Diagnostic Centers, by Hepatitis B
6.1.2.2.2 Diagnostic Centers, by HIV AIDS
6.1.2.2.3 Diagnostic Centers, by HPV
6.1.2.2.4 Diagnostic Centers, by Herpes Simplex Virus(HSV)
6.1.2.2.5 Diagnostic Centers, by Neisseria gonorrhoeae
6.1.2.2.6 Diagnostic Centers, by Other STIs
6.1.3 Out-Patient Clinics/General Practitioners
6.1.3.1 Out-Patient Clinics/General Practitioners, by Respiratory Infections Molecular Diagnostics Market
6.1.3.1.1 Out-Patient Clinics/General Practitioners, by Influenza A and B
6.1.3.1.2 Out-Patient Clinics/General Practitioners, by COVID-19 Infections
6.1.3.1.3 Out-Patient Clinics/General Practitioners, by Respiratory Syncytial Virus
6.1.3.1.4 Out-Patient Clinics/General Practitioners, by Mycoplasma Infection
6.1.3.1.5 Out-Patient Clinics/General Practitioners, by Pertussis
6.1.3.1.6 Out-Patient Clinics/General Practitioners, by Other Respiratory Infections
6.1.3.2 Out-Patient Clinics/General Practitioners Sexually Transmitted Infections (STIs) Market
6.1.3.2.1 Out-Patient Clinics/General Practitioners, by Hepatitis B
6.1.3.2.2 Out-Patient Clinics/General Practitioners, by HIV AIDS
6.1.3.2.3 Out-Patient Clinics/General Practitioners, by HPV
6.1.3.2.4 Out-Patient Clinics/General Practitioners, by Herpes Simplex Virus(HSV)
6.1.3.2.5 Out-Patient Clinics/General Practitioners, by Neisseria gonorrhoeae
6.1.3.2.6 Out-Patient Clinics/General Practitioners, by Other STIs
6.1.4 Research Laboratories
6.1.4.1 Research Laboratories, by Respiratory Infections Molecular Diagnostics Market
6.1.4.1.1 Research Laboratories, by Influenza A and B
6.1.4.1.2 Research Laboratories, by COVID-19 Infections
6.1.4.1.3 Research Laboratories, by Respiratory Syncytial Virus
6.1.4.1.4 Research Laboratories, by Mycoplasma Infection
6.1.4.1.5 Research Laboratories, by Pertussis
6.1.4.1.6 Research Laboratories, by Other Respiratory Infections
6.1.4.2 Research Laboratories Sexually Transmitted Infections (STIs) Market
6.1.4.2.1 Research Laboratories, by Hepatitis B
6.1.4.2.2 Research Laboratories, by HIV AIDS
6.1.4.2.3 Research Laboratories, by HPV
6.1.4.2.4 Research Laboratories, by Herpes Simplex Virus(HSV)
6.1.4.2.5 Research Laboratories, by Neisseria gonorrhoeae
6.1.4.2.6 Research Laboratories, by Other STIs
6.1.5 Other End Users
7.1 Overview
7.2 North America
7.2.1 North America Molecular Diagnostics Market (by Application)
7.2.1.1 North America Respiratory Infections Molecular Diagnostics Market
7.2.1.1.1 North America, by Influenza A and B
7.2.1.1.2 North America, by COVID-19 Infections
7.2.1.1.3 North America, by Respiratory Syncytial Virus
7.2.1.1.4 North America, by Mycoplasma Infection
7.2.1.1.5 North America, by Pertussis
7.2.1.1.6 North America, by Other Respiratory Infections
7.2.1.2 North America Sexually Transmitted Infections (STIs) Market
7.2.1.2.1 North America, by Hepatitis B
7.2.1.2.2 North America, by HIV AIDS
7.2.1.2.3 North America, by HPV
7.2.1.2.4 North America, by Herpes Simplex Virus(HSV)
7.2.1.2.5 North America, by Neisseria gonorrhoeae
7.2.1.2.6 North America, by Other STIs
7.2.2 North America Molecular Diagnostics Market (by End User)
7.2.3 U.S.
7.2.4 Canada
7.3 Europe
7.3.1 Europe Molecular Diagnostics Market (by Application)
7.3.1.1 Europe Respiratory Infections Molecular Diagnostics Market
7.3.1.1.1 Europe, by Influenza A and B
7.3.1.1.2 Europe , by COVID-19 Infections
7.3.1.1.3 Europe, by Respiratory Syncytial Virus
7.3.1.1.4 Europe, by Mycoplasma Infection
7.3.1.1.5 Europe, by Pertussis
7.3.1.1.6 Europe, by Other Respiratory Infections
7.3.1.2 Europe Sexually Transmitted Infections (STIs) Market
7.3.1.2.1 Europe, by Hepatitis B
7.3.1.2.2 Europe, by HIV AIDS
7.3.1.2.3 Europe, by HPV
7.3.1.2.4 Europe, by Herpes Simplex Virus (HSV)
7.3.1.2.5 Europe, by Neisseria gonorrhoeae
7.3.1.2.6 Europe, by Other STIs
7.3.2 Europe Molecular Diagnostics Market (by End User)
7.3.3 Germany
7.3.4 U.K.
7.3.5 France
7.3.6 Italy
7.3.7 Spain
7.3.8 Rest-of-Europe
7.4 Asia-Pacific (APAC)
7.4.1 Asia-Pacific Molecular Diagnostics Market (by Application)
7.4.1.1 Asia-Pacific Respiratory Infections Molecular Diagnostics Market
7.4.1.1.1 Asia-Pacific, by Influenza A and B
7.4.1.1.2 Asia-Pacific , by COVID-19 Infections
7.4.1.1.3 Asia-Pacific, by Respiratory Syncytial Virus
7.4.1.1.4 Asia-Pacific, by Mycoplasma Infection
7.4.1.1.5 Asia-Pacific, by Pertussis
7.4.1.1.6 Asia-Pacific, by Other Respiratory Infections
7.4.1.2 Asia-Pacific Sexually Transmitted Infections (STIs) Market
7.4.1.2.1 Asia-Pacific, by Hepatitis B
7.4.1.2.2 Asia-Pacific, by HIV AIDS
7.4.1.2.3 Asia-Pacific, by HPV
7.4.1.2.4 Asia-Pacific, by Herpes Simplex Virus (HSV)
7.4.1.2.5 Asia-Pacific, by Neisseria gonorrhoeae
7.4.1.2.6 Asia-Pacific, by Other STIs
7.4.2 Asia-Pacific Molecular Diagnostics Market (by End User)
7.4.3 China
7.4.4 India
7.4.5 Japan
7.4.6 Australia
7.4.7 Singapore
7.4.8 Rest-of-Asia-Pacific
7.5 Latin America (LATAM)
7.5.1 Latin America Molecular Diagnostics Market (by Application)
7.5.1.1 Latin America Respiratory Infections Molecular Diagnostics Market
7.5.1.1.1 Latin America, by Influenza A and B
7.5.1.1.2 Latin America, by COVID-19 Infections
7.5.1.1.3 Latin America, by Respiratory Syncytial Virus
7.5.1.1.4 Latin America, by Mycoplasma Infection
7.5.1.1.5 Latin America, by Pertussis
7.5.1.1.6 Latin America, by Other Respiratory Infections
7.5.1.2 Latin America Sexually Transmitted Infections (STIs) Market
7.5.1.2.1 Latin America, by Hepatitis B
7.5.1.2.2 Latin America, by HIV AIDS
7.5.1.2.3 Latin America, by HPV
7.5.1.2.4 Latin America, by Herpes Simplex Virus (HSV)
7.5.1.2.5 Latin America, by Neisseria gonorrhoeae
7.5.1.2.6 Latin America, by Other STIs
7.5.2 Latin America Molecular Diagnostics Market (by End User)
7.5.3 Brazil
7.5.4 Mexico
7.5.5 Rest-of-Latin America
7.6 Rest-of-the-World (RoW)
7.6.1 Rest-of-the-World Molecular Diagnostics Market (by Application)
7.6.2 Rest-of-the-World Molecular Diagnostics Market (by End User)
7.6.2.1 Rest-of-the-World Respiratory Infections Molecular Diagnostics Market
7.6.2.2 Rest-of-the-World Sexually Transmitted Infections (STIs) Market
8.1 Overview
8.2 Abbott
8.2.1 Company Overview
8.2.2 Role of Abbott in the Global Molecular Diagnostics Market
8.2.3 Financials
8.2.4 Key Insights about Financial Health of the Company
8.2.5 SWOT Analysis
8.3 Agilent Technologies, Inc.
8.3.1 Company Overview
8.3.2 Role of Agilent Technologies, Inc. in the Global Molecular Diagnostics Market
8.3.3 Financials
8.3.4 Key Insights about Financial of the Company
8.3.5 SWOT Analysis
8.4 Becton, Dickinson and Company (BD)
8.4.1 Company Overview
8.4.2 Role of Becton, Dickinson and Company (BD) in the Global Molecular Diagnostics Market
8.4.3 Financials
8.4.4 Key Insights about Financial Health of the Company
8.4.5 SWOT Analysis
8.5 bioMérieux SA
8.5.1 Company Overview
8.5.2 Role of bioMérieux SA in the Global Molecular Diagnostics Market
8.5.3 Financials
8.5.4 Key Insights about Financial Health of the Company
8.5.5 SWOT Analysis
8.6 Bio-Rad Laboratories, Inc.
8.6.1 Company Overview
8.6.2 Role of Bio-Rad Laboratories, Inc. in the Global Molecular Diagnostics Market
8.6.3 Financials
8.6.4 Key Insights about Financial Health of the Company
8.6.5 SWOT Analysis
8.7 Danaher
8.7.1 Company Overview
8.7.2 Role of Danaher in the Global Molecular Diagnostics Market
8.7.3 Financials
8.7.4 Key Insights about Financial Health of the Company
8.7.5 SWOT Analysis
8.8 F. Hoffmann-La Roche Ltd
8.8.1 Company Overview
8.8.2 Role of F. Hoffmann-La Roche Ltd in the Global Molecular Diagnostics Market
8.8.3 Financials
8.8.4 Key Insights about Financial Health of the Company
8.8.5 SWOT Analysis
8.9 Guardant Health
8.9.1 Company Overview
8.9.2 Role of Guardant Health in the Global Molecular Diagnostics Market
8.9.3 Financials
8.9.4 Key Insights about Financial Health of the Company
8.9.5 SWOT Analysis
8.10 HTG Molecular Diagnostics, Inc.
8.10.1 Company Overview
8.10.2 Role of HTG Molecular Diagnostics, Inc. in the Global Molecular Diagnostics Market
8.10.3 Financials
8.10.4 Key Insights about Financial Health of the Company
8.10.5 SWOT Analysis
8.11 Illumina, Inc.
8.11.1 Company Overview
8.11.2 Role of Illumina, Inc. in the Global Molecular Diagnostics Market
8.11.3 Financials
8.11.4 Key Insights about Financial Health of the Company
8.11.5 SWOT Analysis
8.12 Invivoscribe, Inc.
8.12.1 Company Overview
8.12.2 Role of Invivoscribe, Inc. in the Global Molecular Diagnostics Market
8.12.3 SWOT Analysis
8.13 ICON plc
8.13.1 Company Overview
8.13.2 Role of ICON plc in the Global Molecular Diagnostics Market
8.13.3 SWOT Analysis
8.14 LungLife AI, Inc.
8.14.1 Company Overview
8.14.2 Role of LungLife AI, Inc. in the Global Molecular Diagnostics Market
8.14.3 SWOT Analysis
8.15 QIAGEN
8.15.1 Company Overview
8.15.2 Role of QIAGEN in the Global Molecular Diagnostics Market
8.15.3 Financials
8.15.4 Key Insights about Financial Health of the Company
8.15.5 SWOT Analysis
8.16 QuantuMDx Group Ltd.
8.16.1 Company Overview
8.16.2 Role of QuantuMDx Group Ltd. in the Global Molecular Diagnostics Market
8.16.3 SWOT Analysis
8.17 Siemens Healthcare GmbH
8.17.1 Company Overview
8.17.2 Role of Siemens Healthcare GmbH in the Global Molecular Diagnostics Market
8.17.3 Financials
8.17.4 Key Insights about Financial Health of the Company
8.17.5 SWOT Analysis
8.18 Thermo Fisher Scientific Inc.
8.18.1 Company Overview
8.18.2 Role of Thermo Fisher Scientific Inc. in the Global Molecular Diagnostics Market
8.18.3 Financials
8.18.4 Key Insights About Financial Health of the Company
8.18.5 SWOT Analysis
Table 1: Biomarkers for Various Diseases
Table 2: FDA-Approved Drugs with a Companion Diagnostic
Table 3: COVID-19 Impact on Global Molecular Diagnostics Market
Table 4: Products Launched by Various Manufacturers for Molecular Diagnostics Research
Table 5: Registration Criteria for IVD Medical Devices as per the CFDA
Table 6: Approved Next-Generation Sequencing (NGS) Panels in Japan
Table 7: Pathogens Responsible for Different Respiratory Infections
Table 8: Key Biomarker Testing Products for Respiratory Infections Offered by Major Market Players
Table 9: Genetic Tests for Certain Applications
Table 10: Examples of Molecular Diagnostics in Cancer
Table 11: North America Molecular Diagnostics Market (by End User), Thousand Units, 2020, 2025, and 2031
Table 12: Europe Molecular Diagnostics Market (by Application), Thousand Units, 2020, 2025, and 2031
Table 13: Europe Molecular Diagnostics Market (by End User), Thousand Units, 2020,2025 and 2031
Table 14: Asia-Pacific Molecular Diagnostics Market (by Application), Thousand Units, 2020, 2025, and 2031
Table 15: Asia-Pacific Molecular Diagnostics Market (by End User), Thousand Units, 2020, 2025, and 2031
Table 16: Latin America Molecular Diagnostics Market (by Application), Thousand Units, 2020, 2025, and 2031
Table 17: Latin America Molecular Diagnostics Market (by End User), Thousand Units, 2020, 2025, and 2031
Table 18: Rest-of-the-World Molecular Diagnostics Market (by Application), Thousand Units, 2020, 2025, and 2031
Table 19: Rest-of-the-World Molecular Diagnostics Market (by End User), Thousand Units, 2020, 2025, and 2031
Figure 1: Annual NIH Funding in Human Genomics Research, $Billion, FY2013-FY2019
Figure 2: Global Molecular Diagnostics Market (Realistic and Optimistic Scenario), $Million, 2020-2031
Figure 3: Global Molecular Diagnostics Market, Market Dynamics
Figure 4: Share of Key Market Strategies and Developments, January 2017-September 2021
Figure 5: Global Molecular Diagnostics Market Snapshot, $Million, 2020-2031
Figure 6: Global Molecular Diagnostics Market (by Product), $Million, 2020 Vs. 2031
Figure 7: Global Molecular Diagnostics Market (by Technology), $Million, 2020 Vs. 2031
Figure 8: Global Molecular Diagnostics Market (by Application), $Million, 2020 Vs. 2031
Figure 9: Global Molecular Diagnostics Market (by End User), $Million, 2020 Vs. 2031
Figure 10: Global Molecular Diagnostics Market (by Region), $Million, 2020 Vs. 2031
Figure 11: Global Molecular Diagnostics Market Research Methodology
Figure 12: Global Molecular Diagnostics Market: Segmentation
Figure 13: Figure 1.1: Role of Diagnostics in Healthcare
Figure 14: Evolution of Molecular Diagnostics
Figure 15: Classification of Molecular Diagnostics
Figure 16: Global Molecular Diagnostics (MDx) Market, $Million, 2020-2031
Figure 17: Global Molecular Diagnostics Market Size and Growth Potential (Realistic Scenario), $Million, 2020-2031
Figure 18: Global Molecular Diagnostics Market Size and Growth Potential (Conservative Scenario), $Million, 2020-2031
Figure 19: Global Molecular Diagnostics Market Size and Growth Potential (Optimistic Scenario), $Million, 2020-2031
Figure 20: Global Molecular Diagnostics Market - Market Dynamics
Figure 21: Distribution of Cases and Deaths by World Regions and Cancer Types
Figure 22: Personalized Care for Cancer Patients
Figure 23: Impact of COVID-19 on Global Molecular Diagnostics Market
Figure 24: Share of Key Developments and Strategies, January 2017–September 2021
Figure 25: Share of Acquisitions (by Company), January 2017-September 2021
Figure 26: Share of Synergistic Activities (by Company), January 2017-September 2021
Figure 27: Share of Product Launches and Upgradations (by Company), January 2017–September 2021
Figure 28: Share of Business Expansion (by Company), July 2017-August 2021
Figure 29: Market Share Analysis for Global Molecular Diagnostics Market, $Million, 2019 and 2020
Figure 30: Growth Share Analysis of Global Molecular Diagnostics Market (by Technology), 2020-2031
Figure 31: Responsibilities of the National Medical Products Administration (NMPA)
Figure 32: Year-Wise Analysis of Patents Related to Molecular Diagnostics, January 2019- October 2021
Figure 33: Country-Wise Analysis (January 2019-October 2021) of Patents Related to Next-Generation Sequencing
Figure 34: Share of Global Molecular Diagnostics Market (by Product), $Million, 2020 and 2031
Figure 35: Share of Global Molecular Diagnostics Market (by Product), Thousand Units, 2020 and 2031
Figure 36: Global Molecular Diagnostics Market (Systems), $Million, 2020-2031
Figure 37: Global Molecular Diagnostics Market (Systems), Thousand Units, 2020-2031
Figure 38: General Workflow of a Molecular Diagnostic Kit
Figure 39: Global Molecular Diagnostics Market (Kits and Consumables), $Million, 2020-2031
Figure 40: Global Molecular Diagnostics Market (Kits and Consumables), Thousand Units, 2020-2031
Figure 41: Aspects of Software Development
Figure 42: Global Molecular Diagnostics Market (Software and Other Products), $Million, 2020-2031
Figure 43: Global Molecular Diagnostics Market (Software and Other Products), Thousand Units, 2020-2031
Figure 44: Global Molecular Diagnostics Market (by Testing Location)
Figure 45: Share of Global Molecular Diagnostics Market (by Testing Location), $Million, 2020 and 2031
Figure 46: Global Molecular Diagnostics Market (Laboratory Testing), $Million, 2020-2031
Figure 47: Global Molecular Diagnostics Market (Point-of-Care Testing), $Million, 2020-2031
Figure 48: Share of Global Molecular Diagnostics Market (by Technology), $Million, 2020 and 2031
Figure 49: Global Molecular Diagnostics Market (Polymerase Chain Reaction), $Million, 2020-2031
Figure 50: Global Molecular Diagnostics Market (Polymerase Chain Reaction), Thousand Units, 2020-2031
Figure 51: Global Molecular Diagnostics Market (Next-Generation Sequencing), $Million, 2020-2031
Figure 52: Global Molecular Diagnostics Market (Next-Generation Sequencing), Thousand Units, 2020-2031
Figure 53: Global Molecular Diagnostics Market (Isothermal Nucleic Acid Amplification Technology), $Million, 2020-2031
Figure 54: Global Molecular Diagnostics Market (Isothermal Nucleic Acid Amplification Technology), Thousand Units, 2020-2031
Figure 55: Global Molecular Diagnostics Market (Microarray), $Million, 2020-2031
Figure 56: Global Molecular Diagnostics Market (Microarray), Thousand Units, 2020-2031
Figure 57: Global Molecular Diagnostics Market (ISH), $Million, 2020-2031
Figure 58: Global Molecular Diagnostics Market (ISH), Thousand Units, 2020-2031
Figure 59: Global Molecular Diagnostics Market (IHC), $Million, 2020-2031
Figure 60: Global Molecular Diagnostics Market (IHC), Thousand Units, 2020-2031
Figure 61: Global Molecular Diagnostics Market (Other Technologies), $Million, 2020-2031
Figure 62: Global Molecular Diagnostics Market (Other Technologies), Thousand Units, 2020-2031
Figure 63: Global Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
Figure 64: Global Molecular Diagnostics Market (Core Molecular Diagnostics), $Million, 2020-2031
Figure 65: Global Molecular Diagnostics Market (Core Molecular Diagnostics), Thousand Units, 2020-2031
Figure 66: Global Molecular Diagnostics Market (by Core Molecular Diagnostics), $Million, 2020 and 2031
Figure 67: Global Molecular Diagnostics Market (Infectious Disease), $Million, 2020-2031
Figure 68: Global Molecular Diagnostics Market (Infectious Disease), Thousand Units, 2020-2031
Figure 69: Global Molecular Diagnostics Market (by Infectious Disease), $Million, 2020-2031
Figure 70: Global Molecular Diagnostics Market (by Infectious Disease), Thousand Units, 2020-2031
Figure 71: Global Molecular Diagnostics Market (Respiratory Infections), $Million, 2020-2031
Figure 72: Global Molecular Diagnostics Market (Respiratory Infections), Thousand Units, 2020-2031
Figure 73: Global Molecular Diagnostics Market (Influenza A and B), $Million, 2020-2031
Figure 74: Global Molecular Diagnostics Market (Influenza A and B), Thousand Units, 2020-2031
Figure 75: Global Molecular Diagnostics Market (COVID-19 Infections), $Million, 2020-2031
Figure 76: Global Molecular Diagnostics Market (COVID-19 Infections), Thousand Units, 2020-2031
Figure 77: Global Molecular Diagnostics Market (Respiratory Syncytial Virus), $Million, 2020-2031
Figure 78: Global Molecular Diagnostics Market (Respiratory Syncytial Virus), Thousand Units, 2020-2031
Figure 79: Global Molecular Diagnostics Market (Mycoplasma Infections), $Million, 2020-2031
Figure 80: Global Molecular Diagnostics Market (Mycoplasma Infections), Thousand Units, 2020-2031
Figure 81: Global Molecular Diagnostics Market (Pertussis), $Million, 2020-2031
Figure 82: Global Molecular Diagnostics Market (Pertussis), Thousand Units, 2020-2031
Figure 83: Global Molecular Diagnostics Market (Other Respiratory Infections), $Million, 2020-2031
Figure 84: Global Molecular Diagnostics Market (Other Respiratory Infections), Thousand Units, 2020-2031
Figure 85: Global Molecular Diagnostics Market (Hepatitis B), $Million, 2020-2031
Figure 86: Global Molecular Diagnostics Market (Hepatitis B), Thousand Units, 2020-2031
Figure 87: Global Molecular Diagnostics Market (HIV-AIDS), $Million, 2020-2031
Figure 88: Global Molecular Diagnostics Market (HIV-AIDS), Thousand Units, 2020-2031
Figure 89: Global Molecular Diagnostics Market (HPV), $Million, 2020-2031
Figure 90: Global Molecular Diagnostics Market (HPV), Thousand Units, 2020-2031
Figure 91: Global Molecular Diagnostics Market (Herpes Simplex Virus), $Million, 2020-2031
Figure 92: Global Molecular Diagnostics Market (Herpes Simplex Virus), Thousand Units, 2020-2031
Figure 93: Global Molecular Diagnostics Market (Neisseria Gonorrhoeae), $Million, 2020-2031
Figure 94: Global Molecular Diagnostics Market (Neisseria Gonorrhoeae), Thousand Units, 2020-2031
Figure 95: Global Molecular Diagnostics Market (Other STIs), $Million, 2020-2031
Figure 96: Global Molecular Diagnostics Market (Other STIs), Thousand Units, 2020-2031
Figure 97: Global Molecular Diagnostics Market (Hereditary Genetic Testing), $Million, 2020-2031
Figure 98: Global Molecular Diagnostics Market (Hereditary Genetic Testing), Thousand Units, 2020-2031
Figure 99: Global Molecular Diagnostics Market (Blood Donor Screening), $Million, 2020-2031
Figure 100: Global Molecular Diagnostics Market (Blood Donor Screening), Thousand Units, 2020-2031
Figure 101: Clinical Uses of Molecular Diagnostics in Cancer
Figure 102: Global Molecular Diagnostics Market (Oncology), $Million, 2020-2031
Figure 103: Global Molecular Diagnostics Market (Oncology), Thousand Units, 2020-2031
Figure 104: Global Molecular Diagnostics Market (Human Leukocyte Antigen Testing), $Million, 2020-2031
Figure 105: Global Molecular Diagnostics Market (Human Leukocyte Antigen Testing), Thousand Units, 2020-2031
Figure 106: Global Molecular Diagnostics Market (Other Molecular Diagnostics Applications), $Million, 2020-2031
Figure 107: Global Molecular Diagnostics Market (Other Molecular Diagnostics Applications), Thousand Units, 2020-2031
Figure 108: Global Molecular Diagnostics Market (Reproductive Genetics), $Million, 2020-2031
Figure 109: Global Molecular Diagnostics Market (Reproductive Genetics), Thousand Units, 2020-2031
Figure 110: Global Molecular Diagnostics Market (by Reproductive Genetics), $Million, 2020 and 2031
Figure 111: Global Molecular Diagnostics Market (Carrier Screening), $Million, 2020-2031
Figure 112: Global Molecular Diagnostics Market (Carrier Screening), Thousand Units, 2020-2031
Figure 113: Global Molecular Diagnostics Market (NIPT), $Million, 2020-2031
Figure 114: Global Molecular Diagnostics Market (NIPT), Thousand Units, 2020-2031
Figure 115: Global Molecular Diagnostics Market (Pre-Implantation Genetic Testing), $Million, 2020-2031
Figure 116: Global Molecular Diagnostics Market (Pre-Implantation Genetic Testing), Thousand Units, 2020-2031
Figure 117: Global Molecular Diagnostics Market (Infertility Genetic Testing), $Million, 2020-2031
Figure 118: Global Molecular Diagnostics Market (Infertility Genetic Testing), Thousand Units, 2020-2031
Figure 119: Global Molecular Diagnostics Market (Companion Diagnostics), $Million, 2020-2031
Figure 120: Global Molecular Diagnostics Market (Companion Diagnostics), Thousand Units, 2020-2031
Figure 121: Global Molecular Diagnostics Market (Liquid Biopsy), $Million, 2020-2031
Figure 122: Global Molecular Diagnostics Market (Liquid Biopsy), Thousand Units, 2020-2031
Figure 123: Global Molecular Diagnostics Market (Other Applications), $Million, 2020-2031
Figure 124: Global Molecular Diagnostics Market (Other Applications), Thousand Units, 2020-2031
Figure 125: Share of Global Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
Figure 126: Share of Global Molecular Diagnostics Market (by End User), Thousand Units, 2020 and 2031
Figure 127: Global Molecular Diagnostics Market (Hospitals), $Million, 2020-2031
Figure 128: Global Molecular Diagnostics Market (Hospitals), Thousand Units, 2020-2031
Figure 129: Hospitals Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
Figure 130: Hospitals Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
Figure 131: Hospitals Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
Figure 132: Hospitals Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
Figure 133: Hospitals Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
Figure 134: Hospitals Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
Figure 135: Hospitals Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
Figure 136: Hospitals Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
Figure 137: Hospitals Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
Figure 138: Hospitals Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
Figure 139: Hospitals Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
Figure 140: Hospitals Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
Figure 141: Hospitals Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
Figure 142: Hospitals Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
Figure 143: Hospitals Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
Figure 144: Hospitals Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
Figure 145: Diagnostic Centers Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
Figure 146: Hospitals Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
Figure 147: Diagnostic Centers Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
Figure 148: Hospitals Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
Figure 149: Diagnostic Centers Molecular Diagnostics Market, HPV, $Million, 2020-2031
Figure 150: Hospitals Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
Figure 151: Diagnostic Centers Molecular Diagnostics Market, HSV, $Million, 2020-2031
Figure 152: Hospitals Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
Figure 153: Hospitals Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
Figure 154: Hospitals Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
Figure 155: Hospitals Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
Figure 156: Hospitals Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
Figure 157: Global Molecular Diagnostics Market (Diagnostic Centers), $Million, 2020-2031
Figure 158: Global Molecular Diagnostics Market (Diagnostic Centers), Thousand Units, 2020-2031
Figure 159: Diagnostic Centers Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
Figure 160: Diagnostic Centers Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
Figure 161: Diagnostic Centers Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
Figure 162: Diagnostic Centers Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
Figure 163: Diagnostic Centers Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
Figure 164: Diagnostic Centers Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
Figure 165: Diagnostic Centers Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
Figure 166: Diagnostic Centers Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
Figure 167: Diagnostic Centers Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
Figure 168: Diagnostic Centers Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
Figure 169: Diagnostic Centers Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
Figure 170: Diagnostic Centers Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
Figure 171: Diagnostic Centers Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
Figure 172: Diagnostic Centers Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
Figure 173: Diagnostic Centers Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
Figure 174: Diagnostic Centers Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
Figure 175: Diagnostic Centers Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
Figure 176: Diagnostic Centers Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
Figure 177: Diagnostic Centers Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
Figure 178: Diagnostic Centers Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
Figure 179: Diagnostic Centers Molecular Diagnostics Market, HPV, $Million, 2020-2031
Figure 180: Diagnostic Centers Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
Figure 181: Diagnostic Centers Molecular Diagnostics Market, HSV, $Million, 2020-2031
Figure 182: Diagnostic Centers Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
Figure 183: Diagnostic Centers Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
Figure 184: Diagnostic Centers Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
Figure 185: Diagnostic Centers Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
Figure 186: Diagnostic Centers Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
Figure 187: Global Molecular Diagnostics Market (Out-Patient Clinics/General Practitioners), $Million, 2020-2031
Figure 188: Global Molecular Diagnostics Market (Out-Patient Clinics/General Practitioners), Thousand Units, 2020-2031
Figure 189: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
Figure 190: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
Figure 191: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
Figure 192: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
Figure 193: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
Figure 194: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
Figure 195: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
Figure 196: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
Figure 197: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
Figure 198: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
Figure 199: Diagnostic Centers Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
Figure 200: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
Figure 201: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
Figure 202: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
Figure 203: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
Figure 204: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
Figure 205: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
Figure 206: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
Figure 207: Diagnostic Centers Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
Figure 208: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
Figure 209: Diagnostic Centers Molecular Diagnostics Market, HPV, $Million, 2020-2031
Figure 210: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
Figure 211: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, HSV, $Million, 2020-2031
Figure 212: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
Figure 213: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
Figure 214: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
Figure 215: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
Figure 216: Out-Patient Clinics/General Practitioners Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
Figure 217: Global Molecular Diagnostics Market (Research Laboratories), $Million, 2020-2031
Figure 218: Global Molecular Diagnostics Market (Research Laboratories), Thousand Units, 2020-2031
Figure 219: Research Laboratories Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
Figure 220: Research Laboratories Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
Figure 221: Research Laboratories Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
Figure 222: Research Laboratories Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
Figure 223: Research Laboratories Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
Figure 224: Research Laboratories Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
Figure 225: Research Laboratories Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
Figure 226: Research Laboratories Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
Figure 227: Research Laboratories Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
Figure 228: Research Laboratories Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
Figure 229: Research Laboratories Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
Figure 230: Research Laboratories Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
Figure 231: Research Laboratories Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
Figure 232: Research Laboratories Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
Figure 233: Research Laboratories Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
Figure 234: Research Laboratories Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
Figure 235: Research Laboratories Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
Figure 236: Research Laboratories Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
Figure 237: Research Laboratories Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
Figure 238: Research Laboratories Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
Figure 239: Research Laboratories Molecular Diagnostics Market, HPV, $Million, 2020-2031
Figure 240: Research Laboratories Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
Figure 241: Research Laboratories Molecular Diagnostics Market, HSV, $Million, 2020-2031
Figure 242: Research Laboratories Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
Figure 243: Research Laboratories Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
Figure 244: Research Laboratories Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
Figure 245: Research Laboratories Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
Figure 246: Research Laboratories Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
Figure 247: Global Molecular Diagnostics Market (Other End Users), $Million, 2020-2031
Figure 248: Global Molecular Diagnostics Market (Other End Users), Thousand Units, 2020-2031
Figure 249: Global Molecular Diagnostics Market (by Region), $Million, 2020-2031
Figure 250: Share of North America Molecular Diagnostics Market Revenue (by Country), $Million, 2020 and 2031
Figure 251: North America Molecular Diagnostics Market, $Million, 2020-2031
Figure 252: North America Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 253: North America: Market Dynamics
Figure 254: North America Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
Figure 255: North America Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
Figure 256: North America Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
Figure 257: North America Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
Figure 258: North America Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
Figure 259: North America Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
Figure 260: North America Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
Figure 261: North America Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
Figure 262: North America Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
Figure 263: North America Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
Figure 264: North America Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
Figure 265: North America Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
Figure 266: North America Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
Figure 267: North America Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
Figure 268: North America Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
Figure 269: North America Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
Figure 270: North America Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
Figure 271: North America Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
Figure 272: North America Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
Figure 273: North America Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
Figure 274: North America Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
Figure 275: North America Molecular Diagnostics Market, HPV, $Million, 2020-2031
Figure 276: North America Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
Figure 277: North America Molecular Diagnostics Market, HSV, $Million, 2020-2031
Figure 278: North America Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
Figure 279: North America Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
Figure 280: North America Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
Figure 281: North America Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
Figure 282: North America Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
Figure 283: North America Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
Figure 284: U.S. Molecular Diagnostics Market, $Million, 2020-2031
Figure 285: U.S. Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 286: Canada Molecular Diagnostics Market, $Million, 2020-2031
Figure 287: Canada Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 288: Europe Molecular Diagnostics Market (by Country), $Million, 2020 and 2031
Figure 289: Europe Molecular Diagnostics Market, $Million, 2020-2031
Figure 290: Europe Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 291: Europe: Market Dynamics
Figure 292: Europe Molecular Diagnostics Market (by Application), $Million
Figure 293: Europe Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
Figure 294: Europe Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
Figure 295: Europe Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
Figure 296: Europe Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
Figure 297: Europe Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
Figure 298: Europe Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
Figure 299: Europe Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
Figure 300: Europe Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
Figure 301: Europe Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
Figure 302: Europe Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
Figure 303: Europe Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
Figure 304: Europe Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
Figure 305: Europe Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
Figure 306: Europe Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
Figure 307: Europe Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
Figure 308: Europe Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
Figure 309: Europe Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
Figure 310: Europe Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
Figure 311: Europe Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
Figure 312: Europe Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
Figure 313: Europe Molecular Diagnostics Market, HPV, $Million, 2020-2031
Figure 314: Europe Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
Figure 315: Europe Molecular Diagnostics Market, HSV, $Million, 2020-2031
Figure 316: Europe Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
Figure 317: Europe Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
Figure 318: Europe Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
Figure 319: Europe Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
Figure 320: Europe Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
Figure 321: Europe Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
Figure 322: Germany Molecular Diagnostics Market, $Million, 2020-2031
Figure 323: Germany Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 324: U.K. Molecular Diagnostics Market, $Million, 2020-2031
Figure 325: U.K. Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 326: France Molecular Diagnostics Market, $Million, 2020-2031
Figure 327: France Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 328: Italy Molecular Diagnostics Market, $Million, 2020-2031
Figure 329: Italy Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 330: Spain Molecular Diagnostics Market, $Million, 2020-2031
Figure 331: Spain Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 332: Rest-of-Europe Molecular Diagnostics Market, $Million, 2020-2031
Figure 333: Rest-of-Europe Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 334: Asia-Pacific Molecular Diagnostics Market (by Country), $Million, 2020 and 2031
Figure 335: Asia-Pacific Molecular Diagnostics Market, $Million, 2020-2031
Figure 336: Asia-Pacific Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 337: Asia-Pacific: Market Dynamics
Figure 338: Asia-Pacific Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
Figure 339: Asia-Pacific Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
Figure 340: Asia-Pacific Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
Figure 341: Asia-Pacific Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
Figure 342: Asia-Pacific Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
Figure 343: Asia-Pacific Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
Figure 344: Asia-Pacific Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
Figure 345: Asia-Pacific Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
Figure 346: Asia-Pacific Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
Figure 347: Asia-Pacific Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
Figure 348: Asia-Pacific Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
Figure 349: Asia-Pacific Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
Figure 350: Asia-Pacific Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
Figure 351: Asia-Pacific Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
Figure 352: Asia-Pacific Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
Figure 353: Asia-Pacific Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
Figure 354: Asia-Pacific Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
Figure 355: Asia-Pacific Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
Figure 356: Asia-Pacific Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
Figure 357: Asia-Pacific Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
Figure 358: Asia-Pacific Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
Figure 359: Asia-Pacific Molecular Diagnostics Market, HPV, $Million, 2020-2031
Figure 360: Asia-Pacific Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
Figure 361: Asia-Pacific Molecular Diagnostics Market, HSV, $Million, 2020-2031
Figure 362: Asia-Pacific Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
Figure 363: Asia-Pacific Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
Figure 364: Asia-Pacific Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
Figure 365: Asia-Pacific Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
Figure 366: Asia-Pacific Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
Figure 367: Asia-Pacific Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
Figure 368: China Molecular Diagnostics Market, $Million, 2020-2031
Figure 369: China Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 370: India Molecular Diagnostics Market, $Million, 2020-2031
Figure 371: India Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 372: Japan Molecular Diagnostics Market, $Million, 2020-2031
Figure 373: Japan Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 374: Australia Molecular Diagnostics Market, $Million, 2020-2031
Figure 375: Australia Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 376: Singapore Molecular Diagnostics Market, $Million, 2020-2031
Figure 377: Singapore Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 378: Rest-of-Asia-Pacific Molecular Diagnostics Market, $Million, 2020-2031
Figure 379: Rest-of-Asia-Pacific Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 380: Latin America Molecular Diagnostics Market (by Country), $Million 2020-2031
Figure 381: Latin America Molecular Diagnostics Market, $Million, 2020-2031
Figure 382: Latin America Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 383: LATAM: Market Dynamics
Figure 384: Latin America Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
Figure 385: Latin America Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
Figure 386: Latin America Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
Figure 387: Latin America Molecular Diagnostics Market, Influenza A and B, $Million, 2020-2031
Figure 388: Latin America Molecular Diagnostics Market, Influenza A and B, Thousand Units, 2020-2031
Figure 389: Latin America Molecular Diagnostics Market, COVID-19 Infections, $Million, 2020-2031
Figure 390: Latin America Molecular Diagnostics Market, COVID-19 Infections, Thousand Units, 2020-2031
Figure 391: Latin America Molecular Diagnostics Market, Respiratory Syncytial Virus, $Million, 2020-2031
Figure 392: Latin America Molecular Diagnostics Market, Respiratory Syncytial Virus, Thousand Units, 2020-2031
Figure 393: Latin America Molecular Diagnostics Market, Mycoplasma Infection, $Million, 2020-2031
Figure 394: Latin America Molecular Diagnostics Market, Mycoplasma Infection, Thousand Units, 2020-2031
Figure 395: Latin America Molecular Diagnostics Market, Pertussis, $Million, 2020-2031
Figure 396: Latin America Molecular Diagnostics Market, Pertussis, Thousand Units, 2020-2031
Figure 397: Latin America Molecular Diagnostics Market, Other Respiratory Infections, $Million, 2020-2031
Figure 398: Latin America Molecular Diagnostics Market, Other Respiratory Infections, Thousand Units, 2020-2031
Figure 399: Latin America Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
Figure 400: Latin America Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
Figure 401: Latin America Molecular Diagnostics Market, Hepatitis B, $Million, 2020-2031
Figure 402: Latin America Molecular Diagnostics Market, Hepatitis B, Thousand Units, 2020-2031
Figure 403: Latin America Molecular Diagnostics Market, HIV AIDS, $Million, 2020-2031
Figure 404: Latin America Molecular Diagnostics Market, HIV AIDS, Thousand Units, 2020-2031
Figure 405: Latin America Molecular Diagnostics Market, HPV, $Million, 2020-2031
Figure 406: Latin America Molecular Diagnostics Market, HPV, Thousand Units, 2020-2031
Figure 407: Latin America Molecular Diagnostics Market, HSV, $Million, 2020-2031
Figure 408: Latin America Molecular Diagnostics Market, HSV, Thousand Units, 2020-2031
Figure 409: Latin America Molecular Diagnostics Market, Neisseria gonorrhoeae, $Million, 2020-2031
Figure 410: Latin America Molecular Diagnostics Market, Neisseria gonorrhoeae, Thousand Units, 2020-2031
Figure 411: Latin America Molecular Diagnostics Market, Other STIs, $Million, 2020-2031
Figure 412: Latin America Molecular Diagnostics Market, Other STIs, Thousand Units, 2020-2031
Figure 413: Latin America Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
Figure 414: Brazil Molecular Diagnostics Market, $Million, 2020-2031
Figure 415: Brazil Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 416: Mexico Molecular Diagnostics Market, $Million, 2020-2031
Figure 417: Mexico Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 418: Rest-of-Latin America Molecular Diagnostics Market, $Million, 2020-2031
Figure 419: Rest-of-Asia-Pacific Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 420: Rest-of-the-World Molecular Diagnostics Market, $Million, 2020-2031
Figure 421: Rest-of-the-World Molecular Diagnostics Market, Thousand Units, 2020-2031
Figure 422: Rest-of-the-World Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
Figure 423: Rest-of-the-World Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
Figure 424: Rest-of-the-World Molecular Diagnostics Market, Respiratory Infections, $Million, 2020-2031
Figure 425: Rest-of-the-World Molecular Diagnostics Market, Respiratory Infections, Thousand Units, 2020-2031
Figure 426: Share of Rest-of-the-World Market (by Respiratory Infections), $Million, 2020 and 2031
Figure 427: Rest-of-the-World Molecular Diagnostics Market, Sexually Transmitted Infections, $Million, 2020-2031
Figure 428: Rest-of-the-World Molecular Diagnostics Market, Sexually Transmitted Infections, Thousand Units, 2020-2031
Figure 429: Share of Rest-of-the-World Market (by Sexually Transmitted Infections), $Million, 2020 and 2031
Figure 430: Share of Key Companies Profiled
Figure 431: Abbott: Overall Product Portfolio
Figure 432: Abbott: Overall Financials, 2018-2020
Figure 433: Abbott: Revenue (by Segment), 2018-2020
Figure 434: Abbott: Revenue (by Region), 2018-2020
Figure 435: Abbott: R&D Expenditure, 2018-2020
Figure 436: Abbott: SWOT Analysis
Figure 437: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 438: Agilent Technologies, Inc.: Overall Financials, 2018-2020
Figure 439: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 440: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 441: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 442: Agilent Technologies, Inc.: SWOT Analysis
Figure 443: Becton, Dickinson and Company (BD): Overall Product Portfolio
Figure 444: Becton, Dickinson and Company (BD): Overall Financials, 2018-2020
Figure 445: Becton, Dickinson and Company (BD): Revenue (by Segment), 2018-2020
Figure 446: Becton, Dickinson and Company (BD): Revenue (by Region), 2018-2020
Figure 447: Becton, Dickinson and Company (BD): R&D Expenditure, 2018-2020
Figure 448: Becton, Dickinson and Company: SWOT Analysis
Figure 449: bioMérieux SA: Overall Product Portfolio
Figure 450: bioMérieux SA: Overall Financials, 2018-2020
Figure 451: bioMérieux SA: Revenue (by Segment), 2018-2020
Figure 452: bioMérieux SA: Revenue (by Region), 2018-2020
Figure 453: bioMérieux SA: R&D Expenditure, 2018-2020
Figure 454: bioMérieux SA: SWOT Analysis
Figure 455: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 456: Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
Figure 457: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020
Figure 458: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
Figure 459: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020
Figure 460: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 461: Danaher: Overall Product Portfolio
Figure 462: Danaher: Overall Financials, 2018-2020
Figure 463: Danaher: Revenue (by Segment), 2018-2020
Figure 464: Danaher: Revenue (by Region), 2018-2020
Figure 465: Danaher: R&D Expenditure, 2018-2020
Figure 466: Danaher: SWOT Analysis
Figure 467: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 468: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
Figure 469: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2018-2020
Figure 470: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2018-2020
Figure 471: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
Figure 472: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 473: Guardant Health: Overall Product Portfolio
Figure 474: Guardant Health: Overall Financials, 2018-2020
Figure 475: Guardant Health: Revenue (by Segment), 2018-2020
Figure 476: Guardant Health: R&D Expenditure, 2018-2020
Figure 477: Guardant Health: SWOT Analysis
Figure 478: HTG Molecular Diagnostics, Inc.: Overall Product Portfolio
Figure 479: HTG Molecular Diagnostics, Inc.: Overall Financials, 2018-2020
Figure 480: HTG Molecular Diagnostics, Inc.: Revenue (by Segment), 2018-2020
Figure 481: HTG Molecular Diagnostics, Inc.: R&D Expenditure, 2018-2020
Figure 482: HTG Molecular Diagnostics, Inc.: SWOT Analysis
Figure 483: Illumina, Inc.: Overall Product Portfolio
Figure 484: Illumina, Inc.: Overall Financials, 2018-2020
Figure 485: Illumina, Inc.: Revenue (by Segment), 2018-2020
Figure 486: Illumina, Inc.: Revenue (by Region), 2018-2020
Figure 487: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 488: Illumina, Inc.: SWOT Analysis
Figure 489: Invivoscribe, Inc.: Overall Product Portfolio
Figure 490: Invivoscribe, Inc.: SWOT Analysis
Figure 491: ICON plc: Overall Product Portfolio
Figure 492: ICON plc: SWOT Analysis
Figure 493: LungLife AI, Inc.: Overall Product Portfolio
Figure 494: LungLife AI, Inc.: SWOT Analysis
Figure 495: QIAGEN: Overall Product Portfolio
Figure 496: QIAGEN: Overall Financials, 2018-2020
Figure 497: QIAGEN: Revenue (by Segment), 2018-2020
Figure 498: QIAGEN: Revenue (by Region), 2018-2020
Figure 499: QIAGEN: R&D Expenditure, 2018-2020
Figure 500: QIAGEN: SWOT Analysis
Figure 501: QuantuMDx Group Ltd.: Overall Product Portfolio
Figure 502: QuantuMDx Group Ltd.: SWOT Analysis
Figure 503: Siemens Healthcare GmbH: Overall Product Portfolio
Figure 504: Siemens Healthcare GmbH: Overall Financials, 2018-2020
Figure 505: Siemens Healthcare GmbH: Revenue (by Segment), 2018-2020
Figure 506: Siemens Healthcare GmbH: Revenue (by Region), 2018-2020
Figure 507: Siemens Healthcare GmbH: R&D Expenditure, 2018-2020
Figure 508: Siemens Healthcare GmbH: SWOT Analysis
Figure 509: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 510: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
Figure 511: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2018-2020
Figure 512: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 513: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 514: Thermo Fisher Scientific Inc.: SWOT Analysis
Market Report Coverage
|
Molecular Diagnostics Market |
|||
|
Base Year |
2020 |
Market Size in 2020 |
$10,914.6 Million |
|
Forecast Period |
2021-2031 |
Value Projection and Estimation by 2031 |
$24,228.0 Million |
|
CAGR During Forecast Period |
7.38% |
Number of Table |
19 |
|
Number of Pages |
468 |
Number of Figures |
514 |
|
Market Segmentation |
• Products (Kits and Consumables, Systems, Software and Other Products) • Testing Location (Laboratory Testing and Point-of-Care (POC) Testing) • Application (Core Molecular Diagnostics, Reproductive Genetics, Companion Diagnostics (CDx), Liquid Biopsy, and Others) • Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing, Isothermal Nucleic Acid Amplification Technology (INAAT), Microarray, In-situ Hybridization (ISH), Immunohistochemistry (IHC) and Other Technologies) • End User (Hospitals, Diagnostics Centers, Out-Patient Clinics/General Practitioners, Research Laboratories, and Other End Users) |
||
|
Regional Segmentation |
• North America: U.S., Canada • Europe: Germany, France, Italy, U.K., Spain, and Rest-of- Europe • Asia-Pacific: Japan, China, India, Australia, Singapore, and Rest-of-Asia-Pacific • Latin America: Brazil, Mexico, Rest-of-Latin America • Rest-of-the-World (RoW) |
||
|
Market Growth Drivers |
• A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally • Growth in the Biomarker Identification Market and Advancements in Molecular Techniques • Increase in Awareness and Acceptance of Personalized Medicines on a Global Level • Significant External Funding for Executing Research and Development Exercises |
||
|
Market Challenges |
• Uncertain Reimbursement Scenario • Lack of High-Complexity Testing Centers • Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests |
||
|
Market Opportunities |
• Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations • Rise of Next-Generation Ultrasensitive Molecular Diagnostics • Novel Revenue Streams |
||
|
Key Companies Profiled |
Abbott, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Guardant Health, HTG Molecular Diagnostics, Inc., Illumina, Inc., Invivoscribe, Inc., ICON plc, LungLife AI, Inc., QIAGEN, QuantuMDx Group Ltd., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc. |
||
Key Questions Answered in this Report:
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
• What are the major market drivers, challenges, and opportunities in the global molecular diagnostics market?
• What are the underlying structures resulting in the emerging trends within the global molecular diagnostics market?
• How is each segment of the global molecular diagnostics market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
• What are the key developmental strategies implemented by the major players to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for molecular diagnostics?
• Who are the leading players with significant offerings to the global molecular diagnostics market? What is the current market dominance for each of these leading players?
• What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which molecular diagnostic product type has the most promising growth?
• What are the key applications in the global molecular diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
• What are the major technologies that are employed in the global molecular diagnostics market? Which is the dominating technology?
• Who are the primary end-users of the global molecular diagnostics market? Which is the fastest-growing end-user segment in the global molecular diagnostics market?
• Who are the key manufacturers in the global molecular diagnostics market, and what are their contributions? Also, what is the growth potential of each major molecular diagnostics manufacturer?
• What is the scope of the global molecular diagnostics market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which molecular diagnostics application and end user dominate these regions?
• What are the emerging trends in the global molecular diagnostics market? How are these trends revolutionizing the diagnostic procedure?
• Which technologies are anticipated to break through the current molecular diagnostic regime?
• Which companies are anticipated to be highly disruptive in the future and why?
• What are the regulatory procedures that are required to unify the approval process for emerging molecular diagnostics? How will these enhance the reimbursement scenario?
• What are the gaps in regularizing optimum molecular diagnostic adoption in regular healthcare routines? How are these gaps being tackled?
Report Summary
Market Overview
Diagnostic tests provide critical insights at every stage of medical care - right from the genetic tests providing information about personalized cancer treatment to the microbial culture identifying accurate antibiotics against an infection. The importance of diagnostic tests throughout the entire procedure (i.e., prevention, detection, diagnosis, treatment, and successful management of health conditions) of treating an individual for a particular disease is as consequential as the treatment itself. It has been subjected to extensive research for further refinement of the same.
Our healthcare experts have found the molecular diagnostics market to be one of the stable markets, and the global market is predicted to grow from $10,914.6 million in 2020 to $24,228.0 million in 2031 and is expected to grow with a CAGR of 7.38% during the forecast period 2021-2031.
Factors fueling the growth of the market include a highly increasing prevalence of infectious diseases and various types of cancer, an increase in awareness and acceptance of personalized medicines on a global level, and significant external funding for executing research and development exercises. Despite rapid advanced industry growth, several key issues need to be addressed to facilitate future growth. Uncertain reimbursement scenarios, lack of high-complexity testing centers, and complex regulatory frameworks delaying the approval of new molecular diagnostic tests are hampering the market growth. Further, some of the opportunities, such as massive scope for the adoption of molecular diagnostics in emerging nations and the rise of next-generation ultrasensitive molecular diagnostics and novel revenue streams, provide growth to the market.
Within the research report, the market has been segmented based on product, testing location, application, technology, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the prevalence of infectious diseases and various types of cancer globally has created a buzz among companies to invest in advanced technologies such as molecular diagnostics.
Based on region, North America holds the largest share, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period.
Molecular Diagnostics Market - A Global and Regional Analysis
Focus on Product, Testing Location, Application, Technology, and End User - Analysis and Forecast, 2021-2031
Some Faq's
Frequently Asked Questions
The global molecular diagnostics market is predicted to grow from $10,914.6 million in 2020 to $24,228.0 million in 2031 and is expected to grow with a CAGR of 7.38% during the forecast period 2021-2031.
The top market players are Abbott, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Guardant Health, HTG Molecular Diagnostics, Inc., Illumina, Inc., Invivoscribe, Inc., ICON plc, LungLife AI, Inc., QIAGEN, QuantuMDx Group Ltd., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc.
Factors driving the growth of the global molecular diagnostics are a highly increasing prevalence of infectious diseases and various types of cancer, an increase in awareness and acceptance of personalized medicines on a global level, and significant external funding for executing research and development exercises.
Some of the main challenges restricting the growth of the global molecular diagnostics are uncertain reimbursement scenario, lack of high-complexity testing centers, and complex regulatory frameworks delaying the approval of new molecular diagnostic tests.
The potential opportunities that are likely to boost the growth of the global molecular diagnostics are massive scope for adoption of molecular diagnostics in emerging nations, rise of next-generation ultrasensitive molecular diagnostics, and novel revenue streams.
Similar Product
You may also like
Published Year: 2020
Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Coun
The global precision medicine market is set to witness a CAGR of 11.13% during the period...
Published Year: 2020
Global Companion Diagnostics Market: Focus on Technology, Application Area, Country Data (12 Countri
The global companion diagnostics market to grow at a significant CAGR of 12.45% during the...